Severe aplastic anemia (SAA) patients unresponsive to initial immunosuppressive therapy or those who experience clonal evolution will be considered for transplantation using an alternative donor. 1 Alternative donors, including haploidentical family donors have been reported. 2 Transplants with haploidentical donors are considered to be at high risk of adverse outcome. 3 When the partially matched family donor transplant option was initially used, it was unsuccessful owing to the high rate of graft failure (GF) and refractory GvHD, despite its ability to render donors available to almost all patients. 2, 4 Delayed immune recovery and the high incidence of infection were also major clinical obstacles. 5, 6 These drawbacks affect the universal use of haploidentical hematopoietic stem cell transplantation (Haplo-HSCT) for SAA. Although haplo-HSCT has been greatly improved during the past decade, they are usually regarded as a third-line treatment for SAA. 7 We retrospectively summarized 26 patients who failed to respond to previous therapy and underwent haplo-HSCT. The current report discusses the outcomes of haplo-HSCT treatment options in patients with SAA for whom no HLA-identical donor was available at the First Affiliated Hospital of Soochow University and the Second People's Hospital of Huai'an from 2005 to 2013.
Between July 2005 and December 2013, 26 Chinese SAA patients who failed to respond to previous therapy, with antithymocyte immunoglobulin and CsA in 4 and CsA alone in 22 patients, with a median interval from diagnosis to transplantation of 5 months (3.7-120) and underwent haplo-HSCT (male, 15 patients; female, 11 patients; median age, 26 years (range, 10-54)) from the First Affiliated Hospital of Soochow University and the Second People's Hospital of Huai'an were enrolled in this study. All patients provided written informed consent for the protocol. This study was approved by the First Affiliated Hospital of Soochow University and the Second People's Hospital of Huai'an Ethics Committee.
Iron chelation therapy (desferrioxamine mesylate for injection) was administered (for median application time 1.5 months (0.7-3)) in 12 patients when the serum ferritin was 41000 μg/L to render it lower than 1000 μg/L before transplantation. 8 Haplo-HSCT was treated with the busulfan/cyclophosphamide (BU/CY)-based regimen that consisted of the following regimen: BU: 3.2 mg/kg/day IV on days − 7 and − 6; CY: 50 mg/kg/day IV on days − 5 to − 2; antithymocyte immunoglobulin (rabbit, Thymoglobulin, Genzyme, Cambridge, MA, USA): 2.5 mg/kg/day IV on days − 5 to − 2.
Stem cell mobilization of donors was performed using subcutaneous G-CSF (Filgrastim, Kirin, Japan) at 5 μg/kg/day from day − 5. On day 01 bone marrow (BM) grafts were collected by BM aspiration in operation room. The cells to achieve a target mononuclear cell count of 2-4 × 10 8 /kg of recipient weight. On day 02, PBSC were collected by apheresis using a COBESPECTRA device (Gambro BCT, Lakewood, CO, USA). The cells from BM and peripheral blood to achieve a target mononuclear cell count of 6-8 × 10
8 /kg of recipient weight. 2 If the cell count was too low, additional PBSC were collected on the following day until a target CD34 + cell count of 3 × 10 6 /kg was attained. 2 Fresh and unmanipulated BM and PBSC were infused into the recipient on the day of collection. CsA, mycophenolate mofetil and short-term methotrexate (MTX) were administered for acute GvHD (aGvHD) prophylaxis as described in Xu et al.
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In this study, the definition of SAA refers to patients who meet at least two of the following criteria: neutrophil count o0.5 × 10 9 /L, platelet count o20 × 10 9 /L and reticulocyte count (performed by manual counting) o20 × 10 9 /L. 8 Patients with a neutrophil count below 0.2 × 10 9 /L were diagnosed as vSAA. 8 After HSCT, the first time that ANC exceeded 0.5 × 10 9 /L for 3 consecutive days was defined as neutrophil engraftment. First time platelet counts 420 × 10 9 /L without transfusion support for 7 consecutive days was defined as platelet engraftment. Primary GF was defined as failure to achieve neutrophil engraftment after HSCT until day +100 post HSCT. Secondary GF was defined as the development of ANC o0.5 × 10 9 /L after achievement of initial engraftment. Delayed platelet recovery was defined as platelet engraftment 430 days. Relapse was defined as the recurrence of disease. Death without disease progression was defined as transplantation related mortality (TRM). Early mortality was defined as death within the first 60 days after HSCT. Failure-free survival (FFS) was defined as survival with response. Death, engraftment failure, graft rejection and relapse were considered as treatment failures.
Statistical analyses were conducted on the basis of data available from the date of treatment to the date of final patient follow-up on 31 May 2014. The probabilities of overall survival (OS) and FFS were estimated from the time of treatment using the Kaplan-Meier method. Statistical analyses were performed with SPSS version 16.0 (SPSS, Chicago, IL, USA).
A total of 26 patients were enrolled in the study. Characteristics of patients and donors are shown in Table 1 . Median (range) mononuclear cell dose of grafts was 10.07 (5.77-17.76) × 10 8 /kg, CD34 + cell dose was 3.43 (1.54-7.25) × 10 6 /kg. The median (range) time to neutrophil engraftment was 12 (6-28) days, and the median (range) time to platelet engraftment was 19 (12-330) days. There was no primary GF. All patients achieved successful neutrophil engraftment, and four patients experienced delayed platelet engraftment. One patient experienced GF of platelets. One patient experienced secondary GF at 5 months post HSCT. At 6 months after treatment, the treatment failure rate was 19.23% (5/26; Table 2 ). During the follow-up period, there was no patient relapse. No patient developed secondary clonal disease (paroxysmal nocturnal hemoglobinuria, myelodysplastic syndrome (MDS) and leukemia). No patient developed any other clonal disease during the follow-up period (Table 2) . Three patients experienced early mortality. Of these, one patients died because of thrombotic microangiopathy, one patient died because of pulmonary infection and one patient died because of grade IV aGvHD (Table 2) . During the follow-up period, the cumulative incidence rate of TRM was 23.68 ± 9.74%. Causes of death included infection, GvHD and secondary GF ( Table 2) . Among the evaluated patients, a total of 15 patients had aGvHD, 7 patients developed grade II aGvHD, 1 had grade III aGvHD and 2 had grade IV aGvHD. The cumulative incidence rates at 100 days after HSCT of aGvHD, of grades II-IV aGvHD and of grades III and IV aGvHD were 61.52 ± 9.5%, 48.40 ± 10.70% and 15.55 ± 8.48%, respectively. Of these patients, 13 patients experienced chronic GvHD (cGvHD), 3 showed moderate cGvHD and 1 showed severe cGvHD ( Table 2) . The cumulative incidence rates of cGvHD and of moderate-severe cGvHD were 81.07 ± 11.51% and 24.55 ± 11.99%, respectively. Infection was the most frequent complication. In all, 17 (65.38%) of the patients experienced infection. The estimated OS at 3 years was 76.30 ± 9.70% (Figure 1a) . The estimated FFS at 3 years was 76.30 ± 9.70% (Figure 1b) .
HSCT from an alternative donor types including haplo-HSCT and mismatched unrelated donor-HSCT (MMUD-HSCT) are usually regarded as a third-line treatment options for SAA owing to the high rate of GF and refractory GvHD. 1 In this study, data demonstrate that haplo-HSCT as therapy for SAA attained 80.77% treatment success rate at 6 months following treatment. All patients attained successful engraftment. In all, 11.54% (3/26) of the patients developed grade III-IV aGvHD, 4.35% (1/23) experienced severe cGvHD, only one patient died because of GvHD. At 3 years, the estimated OS and FFS all were 78.6 ± 8.8%. The good results we reported was in patients with limited pretreatment and relatively short after the time of diagnosis. Further studies with larger cohorts are needed to derive more conclusive findings.
Tzeng et al. 9 reported that six patients were treated with HLAhaploidentical family donors with a conditioning regimen of CY 200 mg/kg and TBI of 800 cGy, and all patients attained successful Letter to the Editor engraftment. Xu et al. 2 reported haplo-HSCT in the treatment of 19 patients with SAA by conditioning regimen of BU (total dose 6.4 mg/kg) and CY (total dose 200 mg/kg) and no patients experienced primary GF. In this study, 26 haplo-HSCT patients received a conditioning regimen of BU/CY, and all patients attained successful engraftment. This indicated that haplo-HSCT with non-TBI conditioning could attain excellent engraftment. Non-TBI conditioning was found to protect patients from the side effects of irradiation, such as the disruption of physical growth, fertility and hormone production, which are especially problematic in children and adolescent age patients.
For matched sibling donor HSCT, the upper age limit is 40 years, because the risk of GvHD and TRM increases after this age. 10, 11 However, when the patient is older than 40 years, matched sibling donor HSCT can be considered as first-line therapy if suitable, 12 and matched unrelated donor HSCT can be considered a suitable second-line therapy if patients are younger than 50 (or 50-60 years old with good performance status) when initial immunosuppressive therapy shows no response. 8 It is unknown, however, whether SAA patients aged ⩾ 40 years can undergo haplo-HSCT. In the current study, six haplo-HSCT patients were aged ⩾ 40 years (two patients were aged ⩾ 50 years). All the six patients attained successful engraftment. One patient died of secondary GF at 5 months after transplantation and the other five patients survived (range, 7-29 months). Here, two patients experienced grade I aGvHD, two patients experienced grade II aGvHD and three patients experienced mild cGvHD. Because this group only contained six patients, no firm conclusions could be drawn, although all six patients showed excellent results. This will need to be confirmed in a larger study. 
